Why would a provider deny Strattera?

Introduction

Navigating telehealth for ADHD treatment can be confusing, especially with ever-changing regulations around medication prescribing. While stimulant medications (like Adderall and Ritalin) face strict controls as Schedule II substances, non-stimulant options like Strattera (atomoxetine) follow different, generally more flexible rules. This comprehensive guide breaks down the current telehealth landscape for non-stimulant ADHD medications across the United States as of late 2025, helping patients and providers understand what’s possible in their state.

The good news: non-stimulant ADHD medications can typically be prescribed via telehealth in all 50 states, though specific requirements vary. Since Strattera is not a controlled substance, it avoids many of the restrictions that apply to stimulants, making it more accessible through virtual care platforms like Klarity Health.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Federal Regulations: Non-Stimulants vs. Controlled Substances

Non-Stimulant Medications (Like Strattera)

Strattera and other non-stimulant ADHD medications are not controlled substances under the Drug Enforcement Administration (DEA) classification system. This means:

• No federal requirement for an in-person examination before prescribing
• No special DEA registration needed for prescribers
• Electronic prescriptions allowed (but not federally mandated)
• Multiple refills permitted on a single prescription
• 90-day supplies commonly available

Controlled Substance Rules (For Context)

By contrast, stimulant ADHD medications like Adderall and Ritalin are Schedule II controlled substances, which normally would require:

• An in-person examination under the Ryan Haight Act
• Special DEA registration for prescribers
• Limitations on refills (new prescriptions required each time)
• Maximum 30-day supplies

Current Status: The DEA has temporarily waived the in-person requirement for controlled substances through December 31, 2025, under the ‘Third Extension of COVID-19 Telemedicine Flexibilities.’ This allows telehealth prescribing of stimulants without prior in-person visits, but this waiver is set to expire unless extended again.

State-by-State Telehealth Rules for Non-Stimulant ADHD Medications

While federal law creates a baseline, state regulations add additional requirements. Here’s how the landscape looks for non-stimulant ADHD medications across key states:

California

• Telehealth Allowed: Yes, fully permitted
• In-Person Exam Required: None for non-controlled medications
• Prescription Monitoring Program (PMP) Checks: Optional for non-controlled medications
• Provider Authority: Nurse Practitioners have independent practice authority (after meeting experience requirements)
• 2025 Update: AB 1503 proposed to further modernize telehealth definitions but hasn’t passed yet

California maintains one of the most telehealth-friendly environments in the country. Telehealth providers, including those at Klarity Health, can evaluate patients, diagnose ADHD, and prescribe non-stimulant medications like Strattera without requiring any in-person visits.

New York

• Telehealth Allowed: Yes
• In-Person Exam Required: None for non-controlled medications (though required for controlled substances as of 2025)
• PMP Checks: Optional for non-controlled medications
• Provider Authority: Nurse Practitioners can practice independently after 3,600 hours
• 2025 Update: NY implemented a Final Rule requiring in-person exams before prescribing controlled substances via telehealth, but this doesn’t affect non-stimulant medications

New York presents a contrast between stimulant and non-stimulant prescribing rules. While the state reinstated in-person requirements for controlled substances in May 2025, non-stimulant ADHD medications like Strattera remain fully accessible via telehealth without any in-person exam requirement.

Florida

• Telehealth Allowed: Yes
• In-Person Exam Required: None for non-controlled medications
• PMP Checks: Optional for non-stimulants
• Provider Authority: NPs/PAs require physician collaboration
• 2025 Update: Florida’s telehealth rules have remained relatively stable since SB 312 (2022)

Florida allows telehealth providers to prescribe non-stimulant ADHD medications without requiring patients to have prior in-person examinations. The state does have restrictions on controlled substance prescribing via telehealth, but these don’t apply to medications like Strattera.

Texas

• Telehealth Allowed: Yes
• In-Person Exam Required: None for non-controlled medications
• PMP Checks: Optional for non-stimulants
• Provider Authority: NPs/PAs require physician delegation; NPs cannot prescribe Schedule II drugs in outpatient settings
• 2025 Update: No major changes to telehealth laws; bills to expand NP authority did not pass

Texas maintains telehealth-friendly policies, especially for mental health care. Non-stimulant ADHD medications can be prescribed via telehealth platforms by physicians or advanced practice providers working under physician supervision.

Alabama

• Telehealth Allowed: Yes, but with stricter oversight
• In-Person Exam Required: After 4 telehealth visits for the same condition, patients must be seen in-person within 12 months (though mental health services are exempt from this requirement)
• PMP Checks: Optional for non-stimulants
• Provider Authority: NPs/PAs require physician supervision
• 2025 Update: Alabama remains one of the stricter states for telehealth prescribing

Alabama has more restrictive telehealth regulations compared to most states, but the mental health exemption is particularly relevant for ADHD care. This exemption means that ongoing ADHD treatment via telehealth is possible without the in-person visit requirement that applies to many other conditions.

New Hampshire

• Telehealth Allowed: Yes
• In-Person Exam Required: None for non-controlled medications; annual evaluation required for controlled substances (can be via telehealth)
• PMP Checks: Optional for non-stimulants
• Provider Authority: NPs have independent practice authority
• 2025 Update: SB 252 (effective August 2025) expanded telehealth prescribing flexibility

New Hampshire recently modernized its telehealth laws, removing prior in-person requirements and adopting a model that allows ongoing telehealth care with periodic evaluations. This change makes the state significantly more telehealth-friendly than in previous years.

Georgia

• Telehealth Allowed: Yes
• In-Person Exam Required: None for non-controlled medications
• PMP Checks: Optional for non-stimulants
• Provider Authority: NPs/PAs require physician supervision; NPs cannot prescribe Schedule II drugs
• 2025 Update: No major changes to telehealth or prescribing laws

Georgia allows telehealth prescribing of non-stimulant ADHD medications without special restrictions. The state follows standard telehealth practice requirements, making non-stimulant options accessible via virtual care.

Strattera (Atomoxetine) Quick Reference

Who Can Prescribe Non-Stimulant ADHD Medications via Telehealth

• Physicians (MD/DO): Can prescribe in all states if properly licensed
• Nurse Practitioners:
• Can prescribe non-stimulants in all states (either independently or with physician collaboration)
• Authority for stimulants varies widely by state (relevant if patient might later transition)
• Physician Assistants:
• Can prescribe non-stimulants in all states under physician supervision
• Level of required supervision varies by state

What to Expect in a Legitimate Telehealth ADHD Evaluation

A proper telehealth ADHD assessment should include:

1. Comprehensive medical history – Including past diagnoses, treatments, and family history
2. DSM-5 criteria evaluation – Assessing symptoms in multiple settings
3. Rating scales or questionnaires

Source:

• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20Drug%20Enforcement%20Administration%20,Federal%20Register%20on%20Friday%20night
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=visit,examination%20through%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.fiercehealthcare.com/regulatory/dea-finalizes-one-year-extension-controlled-substance-prescribing-telehealth-punts-final#:~:text=The%20%E2%80%9CThird%20Temporary%20Extension%20of,14
• https://www.medicalnewstoday.com/articles/drugs-is-strattera-a-controlled-substance#:~:text=Strattera%20,such%20as%20mental%20health%20issues
• https://www.sheppardhealthlaw.com/2025/08/articles/telehealth/telehealth-and-in-person-visits-tracking-federal-and-state-updates-to-pandemic-era-telehealth-exceptions/#:~:text=In%20late%202024%2C%20the%20U,prescribing
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20,False%20Hope
• https://www.techtarget.com/virtualhealthcare/news/366616019/Telehealth-prescribing-flexibility-extended-through-2025#:~:text=Image%20filo%2FDigitalVision%20Vectors%20via%20G,The
• https://natlawreview.com/article/telehealth-and-person-visits-tracking-federal-and-state-updates-pandemic-era?amp=#:~:text=Extend%20natlawreview,before%20issuing%20a%20dangerous%20drug
• https://www.rxagent.co/blog/telehealth-compliance-trap#:~:text=,specifically%20for%20chronic%20pain%20treatment